DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Propranolol and Amantadine for Cocaine Dependence

Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cocaine Dependence

Intervention: Propranolol (Drug); Amantadine (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: National Institute on Drug Abuse (NIDA)

Official(s) and/or principal investigator(s):
Kyle M Kampman, MD, Principal Investigator, Affiliation: University of Pensylvania


This study evaluates the efficacy of propranolol and amantadine in patients with severe cocaine withdrawal and cocaine craving.

Clinical Details

Official title: A Double-Blind, Placebo Controlled Trial of Propranolol and Amantadine for the Treatment of Cocaine Dependent Subjects With Severe Cocaine Withdrawal Symptoms

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Male and females, 18 to 60 years old.

- Meets DSM-IV criteria for Cocaine Dependence, as determined by the Structured Clinical

Interview for DSM-IV (SCID).

- Initial CSSA score of 22 or greater. This score would place patients at risk of early

treatment attrition and inability to attain abstinence based on previous cocaine pharmacotherapy trials conducted at this center.

- Continued use of cocaine during a two week evaluation phase prior to medication

treatment as demonstrated by at least 2 new uses of cocaine documented by quantitative urine toxicology screen obtained every M, W, F according to new use rules (Preston et al., 1997).

- Live within a commutable distance of the Treatment Research Center (TRC) at the

Penn/VA Center for Studies of Addiction, University of Pennsylvania. We define this to be a distance within the service area of Septa, within an hour drive, or a distance that both the patient and Principal Investigator (PI) find acceptable .

- Understands and signs the informed consent.

Exclusion Criteria:

- Current DSM-IV diagnosis of any psychoactive substance dependence other than cocaine,

marijuana, or nicotine dependence, as determined by the SCID.

- Concomitant treatment with psychotropic medications.

- Patients mandated to treatment based upon a legal decision or as a condition of


This will be assessed by the patient's self-report.

- Current severe psychiatric symptoms, e. g., psychosis, dementia, suicidal or homicidal

ideation, mania or depression requiring antidepressant therapy in the opinion of the Principal Investigator (PI).

- Use of any investigational medication within the past 30 days.

- History of significant heart disease (an arrhythmia which required medication,

Wolff-Parkinson - White Syndrome, angina pectoris, documented history of myocardial

infarction, heart failure).

- History of chest pain associated with cocaine use which has prompted a visit to a


- Current use of reserpine, verapamil, theophylline, trimethoprim, cimetidine,

haloperidol, benzodiazepines, or anticonvulsants.

- Patients with bronchospastic disease, hyperthyroidism, diabetes mellitus.

- Known hypersensitivity to propranolol or amantadine.

- Patients with known AIDS or other serious illnesses which may require hospitalization

during the study.

- Female subjects who are pregnant or lactating, or female subjects of child bearing

potential who are not using acceptable methods of birth control. Acceptable methods of birth control include: barrier (diaphragm or condom) with spermicide, intrauterine progesterone contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection, oral contraceptives.

- Patients with impaired renal function as indicated by corrected creatinine clearance

below 80 ml/min/70 kg as determined by the modified Cockcroft equation (CDC, 1986).

- Clinical laboratory tests (CBC, blood chemistries, urinalysis) outside normal limits

that are clinically unacceptable to the Principal Investigator. EKG?1st degree heart block, sinus tachycardia, left axis deviation, and nonspecific ST or T wave changes are allowed; liver function tests [LFTs] <5 x ULN are acceptable).

Locations and Contacts

University of Pennsylvania, Treatment Research Center, Philadelphia, Pennsylvania 19104, United States
Additional Information

Starting date: February 1999
Ending date: June 2005
Last updated: May 7, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015